Compound Profiles
CJC-1295 (without DAC)
Short-Acting Growth Hormone Releasing Hormone Analog
Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.
Hexarelin
Examorelin | Synthetic Growth Hormone Secretagogue
Hexarelin binds to the growth hormone secretagogue receptor 1a (GHS-R1a) in the brain and pituitary gland. This binding initiates a signaling cascade that stimulates somatotroph cells in the anterior pituitary to produce and release growth hormone.
Combined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take CJC-1295 (without DAC) with Hexarelin?
Yes, but with caution. Can combine but watch for excessive GH elevation. Regular monitoring is advised.
Is CJC-1295 (without DAC) and Hexarelin safe together?
Based on documented research, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting, teratogenic. Monitor accordingly.
What are the interactions between CJC-1295 (without DAC) and Hexarelin?
Can combine but watch for excessive GH elevation. This assessment has 90% confidence and is based on documented research data.
How should I time CJC-1295 (without DAC) and Hexarelin?
CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and Hexarelin has a half-life of 1-2 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.